Timothy Quinn
Urology · New York, NYNPI 1225561343
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Calyxo, Inc. at 48.0% of the total. That places this record below the midpoint for urology clinicians in NY, where the typical reported total is $2,467.
Across 6 payments — averaging $29.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calyxo, Inc.$84
- Baxter Healthcare$42
- Medtronic$20
- Boston Scientific$17
- Hollister Incorporated$12
Across 2 payments — averaging $24,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$48K
What the payments were for
- Food & beverage$174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calyxo, Inc. | 1 | $84 |
| Baxter Healthcare | 2 | $42 |
| Medtronic | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Hollister Incorporated | 1 | $12 |
How this compares
$174 in reported general payments places this provider in the 15th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 23 | $22,701 |
| MyrbetriqMirabegron | 18 | $13,342 |
| Tamsulosin Hcl | 256 | $2,701 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $2,686 |
| Estradiol | 26 | $1,618 |
| Methenamine Hippurate | 19 | $985 |
| Cefpodoxime Proxetil | 18 | $789 |
| Finasteride | 91 | $744 |
| Oxybutynin Chloride ErOxybutynin Chloride | 38 | $652 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $311 |
| Oxybutynin Chloride | 14 | $170 |
| Tolterodine Tartrate | 12 | $156 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 62 | $152 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $116 |
| Ciprofloxacin Hcl | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.